Tim Sloan/AFP/Getty Images

The MyDRUG study will be launched by the Multiple Myeloma Research Foundation, which will focus on assessing treatments specifically for patients with high-risk multiple myeloma to improve therapy matching. "MyDRUG is a major milestone for the MMRF in terms of putting precision medicine to work for patients through our unique end-to-end model, which aims to deliver the right treatment to every patient living with myeloma," said MMRF President and CEO Paul Giusti.

Related Summaries